Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Quinazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 9/20 | 0.95 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL5920 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL29356169 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL22833783 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL29490398 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL4487630 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL21055790 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL1119374 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL19877280 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL167076 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| SCHEMBL3196932 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101367794-A | Preparation method for quinazoline derivants and medical uses thereof | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2009-02-18 | — | — | CN | claimed |
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| EP-1844004-B1 | QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2009-06-24 | — | — | EP | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080114008-A1 | Quinazoline Derivatives as Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| EP-1844004-A1 | QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079833-A1 | QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| CN-1474815-A | 4-amino-quinazolines | Ĭ��ר���ɷ�����˾ | 2004-02-11 | — | — | CN | disclosed |
| CN-1474816-A | 4-amino-quinazolines | Ĭ��ר���ɷ�����˾ | 2004-02-11 | — | — | CN | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| US-4228167-A | Diuretic and vasodilating tricyclic quinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | ACHE 1324/4885EGFR 1117/4885PIK3CD 3828/4885 |
| US-20080114008-A1 | Quinazoline Derivatives as Antiviral Agents | IFNAR1, C5, EIF2AK2 | ACHE 2479/4885EGFR 2163/4885PIK3CD 4179/4885 |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | ACHE 423/4885EGFR 4031/4885PIK3CD 4231/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | ACHE 1044/4885EGFR 1086/4885PIK3CD 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.